{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:59:58Z","timestamp":1780325998768,"version":"3.54.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1053\/j.seminoncol.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:45:06Z","timestamp":1644453906000},"page":"103-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical guidance for new multiple myeloma treatment regimens: A nursing perspective"],"prefix":"10.1053","volume":"49","author":[{"given":"Monica","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candis","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2022.01.010_bib0001","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.010_bib0002","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.010_bib0003","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14656566.2017.1349102","article-title":"Melphalan hydrochloride for the treatment of multiple myeloma","volume":"18","author":"Esma","year":"2017","journal-title":"Expert Opin PharmacOther"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0004","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/jco.2007.25.18_suppl.8019","article-title":"Survival outcomes for multiple myeloma over three decades: a Surveillance, Epidemiology, and End Results (SEER) analysis","volume":"25","author":"Jawed","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.010_bib0005","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.010_bib0006","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5500\/wjt.v6.i2.321","article-title":"First line v delayed transplantation in myeloma: certainties and controversies","volume":"6","author":"Brioli","year":"2016","journal-title":"World J Transplant"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.010_bib0007","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0008","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(63)91346-1","article-title":"Teratogenic effects of thalidomide and related substances","volume":"1","author":"Boylen","year":"1963","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.010_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.010_bib0010","first-page":"301","article-title":"Multiple myeloma: charging toward a bright future","volume":"57","author":"Katzel","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.010_bib0011","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.010_bib0012","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.010_bib0013","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.010_bib0014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.010_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunOtherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0016","first-page":"1961","article-title":"Thalidomide-derived immunomodulatory drugs as therapeutic agents","volume":"4","author":"Galustian","year":"2004","journal-title":"Exp Opin Biolog Ther"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.010_bib0017","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0018","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"ImmunOtherapy combinations in multiple myeloma \u2013 known unknowns","volume":"370","author":"Gormely","year":"2018","journal-title":"NEJM"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0019","unstructured":"Thalidomide (Thalomid) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020785s068lbl.pdf.[Accessed on 25.09.20]."},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.010_bib0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide v melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0021","first-page":"37","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat Cancer"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.010_bib0022","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0023","unstructured":"Lenalidomide (Revlimid) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021880s001.pdf. [Accessed on 25.09.20]."},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.010_bib0024","first-page":"1055","article-title":"Pomalidomide plus low-dose dexamethasone v high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label","volume":"14","author":"Miguel","year":"2013","journal-title":"phase 3 trial. Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0025","unstructured":"Pomalidomide (Pomalyst) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204026s023lbl.pdf. [Accessed on 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0026","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resistance Updates"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0027","unstructured":"Carfilzomib (Kyprolis) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202714s030lbl.pdf. [Accessed on 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0028","unstructured":"Bortezomib (Velcade) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021602s044lbl.pdf [Accessed 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0029","unstructured":"Ixazomib (Ninlaro) [package insert]. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208462lbl.pdf [Accessed 25.09.20]."},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.010_bib0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.010_bib0031","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0032","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.010_bib0033","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneously v intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1053\/j.seminoncol.2022.01.010_bib0034","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0035","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0036","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0037","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0038","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple Myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.010_bib0039","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/10428194.2017.1403020","article-title":"Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity","volume":"59","author":"Lendavi","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0040","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"NEJM"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.010_bib0041","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","article-title":"Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients","volume":"105","author":"Kitadate","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.010_bib0042","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0043","unstructured":"Daratumumab (Darzalex) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761036s004lbl.pdf. [Accessed 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0044","unstructured":"Elotuzumab (Empliciti) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf. [Accessed on 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0045","unstructured":"Isatuximab (Sarclisa) [package insert]. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761113s000lbl.pdf. [Accessed 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0046","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous v intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicenter, open-label, non-inferiority, randomized, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.010_bib0047","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of actin in multiple myeoma in 2013: a report from the international myeloma working group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0048","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival for the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0049","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatusimab plus pomalidomide and low-dose dexamethasone v pomalidomIde and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomized, multicenter, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"The Lancet"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.010_bib0050","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshiima","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0051","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone v placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0052","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s10637-013-9930-2","article-title":"A phase I dose-escalation study of intravenous Panobinostat in patients with lymphoma and solid tumors","volume":"31","author":"Sharma","year":"2013","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.010_bib0053","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":"Phase II trial of the pan-deacetylase inhibitor Panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0054","unstructured":"Panobinostat (Farydak) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205353s000lbl.pdf. [Accessed 25.09.20]."},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.010_bib0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17512433.2016.1096773","article-title":"Panobinostat for the treatment of relapsed or relapsed\/refractory multiple myeloma; pharmacology and clinical outcomes","volume":"9","author":"Richardson","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0056","unstructured":"Selinexor (Xpovio label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212306s001lbl.pdf. [Accessed on 25.09.20]."},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.010_bib0057","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral Selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"JCO"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.010_bib0058","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11523-017-0538-x","article-title":"The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma","volume":"13","author":"Sanchez","year":"2018","journal-title":"Target Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0059","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory ultiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0060","unstructured":"Belantamab (Blenrep) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf. [Accessed on 25.09.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0062","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab v zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized, controlled phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2022.01.010_bib0063","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1188\/11.CJON.S1.66-76","article-title":"Renal complications in multiple myeloma and related disorders: survivorship care plan of the internationsl myeloma foundation nurse leadership board","volume":"15","author":"Faiman","year":"2011","journal-title":"Clin J Oncl Nurs"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0064","first-page":"233","article-title":"Anemia in multiple myeloma","volume":"2","author":"Ludwig","year":"2004","journal-title":"A. Clin Adv Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0065","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The implications of anemia in multiple myeloma","volume":"4","author":"Mittleman","year":"2003","journal-title":"Clinical Lymphoma"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0066","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"the treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0067","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","article-title":"The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study","volume":"37","author":"Silverberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2 Suppl 3","key":"10.1053\/j.seminoncol.2022.01.010_bib0068","first-page":"16","article-title":"Immunologic aspects of blood transfusion","volume":"21","author":"Klein","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0069","first-page":"522","article-title":"Guideline: diagnosis and management of multiple myeloma","volume":"155","author":"Samson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0070","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit vales in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"399","author":"Besarab","year":"1998","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0071","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/ndt\/gfm185","article-title":"Anaemia of CD- The CHOIR study revisited","volume":"22","author":"Singh","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"21","key":"10.1053\/j.seminoncol.2022.01.010_bib0072","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0073","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21239","article-title":"Erythropoiesis stimulating agents are associated with reduced survival in patients with myeloma","volume":"83","author":"Katodritou","year":"2008","journal-title":"Am J of Hem"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.010_bib0074","first-page":"423","article-title":"The ESA APPRISE oncology program: a history of REMS requirments, a review of the data, and an approach to compliance in the hospital","volume":"36","author":"Reeves","year":"2011","journal-title":"PT"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0075","unstructured":"Postmarket drug safety information. US Food and Drug Administration reports, https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-erythropoiesis-stimulating-agents-esa-epoetin-alfa-marketed-procrit-epogen-darbepoetinas [Accessed 18.11.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0076","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0077","unstructured":"Epoetin Alfa (Epogen) label information. US Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103234s5369lbl.pdf [Accessed 25.11.20]."},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0078","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0079","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0080","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodrinic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0081","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0082","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002239900519","article-title":"Alendronate reduces adhesion of human osteoclast-like cells to bone and bone-protein-coated surfaces","volume":"63","author":"Colucci","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0083","article-title":"NCCN Clinical practice guidelines in oncology. multiple myeloma version 2.2012- september 9","year":"2020","journal-title":"NCCN.org"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0084","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomized, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.010_bib0086","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0034-1370793","article-title":"Venous thromboembolism in multiple myeloma","volume":"40","author":"De Stefano","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0087","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1200\/JCO.2018.36.15_suppl.8051","article-title":"Association of venous thromboembolism with increased mortality in patients with multiple myeloma","volume":"36","author":"Schoen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0088","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsbmb.2009.05.001","article-title":"Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion","volume":"116","author":"Kerachian","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.010_bib0089","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","article-title":"Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis","volume":"46","author":"Uaprasert","year":"2010","journal-title":"European J of Cancer"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0090","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.010_bib0091","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","article-title":"Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance","volume":"3","author":"Palumbo","year":"2012","journal-title":"Ther Adv in Drug Saf"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0092","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0093","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0094","first-page":"1783","article-title":"Factors influencing supportive care needs of multiple myeloma patients treated with chemOtherapy","volume":"28","author":"Choo","year":"2020","journal-title":"Supp care in Cancer"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0095","article-title":"The pivotal role of oncology nurses in the care of patients with multiple myeloma","volume":"11","year":"2016","journal-title":"J of Onc Nursing Navigation Survivorship"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0096","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"NEJM"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0097","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM0010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.010_bib0098","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0099","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"NEJM"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0100","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"NEJM"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0101","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple mueloma","volume":"371","author":"a","year":"2014","journal-title":"EJM"},{"key":"10.1053\/j.seminoncol.2022.01.010_bib0102","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide or in combination with low-dose desamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1053\/j.seminoncol.2022.01.010_bib0103","first-page":"8510","article-title":"MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) v highdose dexamethasone (HiDEX) in relapsed\/refractory multiple myeloma (RRMM)","volume":"31","author":"San-Miguel","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"issue":"24","key":"10.1053\/j.seminoncol.2022.01.010_bib0104","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"10245","key":"10.1053\/j.seminoncol.2022.01.010_bib0105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.010_bib0106","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone v lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.010_bib0107","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone v bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.010_bib0108","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminoncol.2022.01.010_bib0109","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1053\/j.seminoncol.2022.01.010_bib0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:57:26Z","timestamp":1758805046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775422000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0093775422000100"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.010","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical guidance for new multiple myeloma treatment regimens: A nursing perspective","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}